Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GlucoTrack, Inc. (NASDAQ: GCTK) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a smaller reporting company and Nasdaq-listed medical device issuer, GlucoTrack uses these filings to disclose information about its implantable Continuous Blood Glucose Monitor (CBGM) program, financial condition, capital structure, and corporate governance.
Through this page, readers can review current reports on Form 8‑K, where GlucoTrack reports material events such as clinical and financial press releases, special stockholder meetings, financing agreements, and warrant repurchases. Registration statements like Form S‑1 detail equity purchase arrangements and potential resales of common stock tied to committed equity facilities, while proxy materials such as DEF 14A describe stockholder proposals related to share issuances and special meetings.
Annual and quarterly reports (Forms 10‑K and 10‑Q, referenced in company communications) contain management’s discussion and analysis of operating results, descriptions of the CBGM development program, and risk factors that include the need for additional capital, clinical and regulatory uncertainties, and other considerations typical for an investigational medical device company. These filings also outline GlucoTrack’s status as a smaller reporting company and its listing on the Nasdaq Capital Market under the symbol GCTK.
On Stock Titan, GlucoTrack filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as equity line terms, private placements, warrant transactions, and clinical disclosure language. Real-time updates from EDGAR, along with structured access to current reports, registration statements, and proxy materials, allow investors and researchers to follow how GlucoTrack describes the evolution of its implantable CBGM platform, financing strategy, and corporate actions in its official SEC record.
Glucotrack, Inc. is calling a special shareholder meeting on March 12, 2026 to approve several key proposals tied to its financing plans and auditor appointment. Shareholders will vote on authorizing full share issuances under a $20 million equity line with Sixth Borough Capital and on issuing shares for 2,067,182 common warrants sold in a December 31, 2025 private placement.
As of January 28, 2026, Glucotrack had 1,011,279 common shares outstanding. If all pre-funded and common warrants from the private placement are exercised, the investor could hold about 3,100,773 shares, or 77.29% of the then-outstanding stock, significantly diluting other holders. The company notes that failure to approve the warrant issuance could prevent it from accessing up to roughly $8 million of potential proceeds and may jeopardize its ability to fund operations, potentially forcing liquidation or bankruptcy.
Shareholders will also vote on ratifying CBIZ as independent auditor for 2025 and on allowing adjournment of the meeting to solicit additional proxies if needed. The board unanimously recommends voting in favor of all four proposals.
Glucotrack, Inc. filed a current report to furnish a press release dated January 29, 2026 under Regulation FD. The company attached the press release as Exhibit 99.1 to provide investors with the same information shared publicly. No financial results or major transactions are described in this excerpt.
Glucotrack, Inc. has registered up to 3,224,803 shares of common stock for resale by existing investors, all issuable from pre-funded, common, and placement agent warrants issued in a December 2025 private placement.
The company will not receive any proceeds from these resale transactions; it previously received approximately $4.0 million in gross proceeds when the warrants were originally sold. As of January 12, 2026, only 910,688 shares of common stock were outstanding, so the registered shares equal about 354% of current shares, creating a large potential overhang that the company warns could significantly pressure its stock price.
Glucotrack is a clinical-stage company developing a fully implantable continuous blood glucose monitor and has reported promising early human data, but it has a long history of losses, substantial doubt about its ability to continue as a going concern, and a challenging Nasdaq listing history that has required multiple reverse stock splits to maintain compliance.
Glucotrack, Inc. is registering 3,224,803 shares of common stock for resale by warrant holders from a December 2025 private placement. The shares consist of 1,033,591 shares underlying pre-funded warrants with a $0.001 exercise price, 2,067,182 shares underlying common warrants with a $3.87 exercise price, and 124,030 shares underlying placement agent warrants with a $4.257 exercise price. Glucotrack will not sell shares or receive proceeds from these resales.
The registered shares equal about 354% of the 910,688 shares outstanding as of January 12, 2026, creating significant potential dilution and stock overhang. The company is a smaller reporting company developing a fully implantable continuous blood glucose monitor and has reported promising first-in-human accuracy data but also substantial historical losses, going concern doubts, and a history of Nasdaq listing compliance issues.
Glucotrack, Inc. furnished an update on its business by announcing it issued a press release with financial and operating results for the third quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1 to a Form 8-K dated November 13, 2025, under Item 2.02. The information is furnished, not filed, and therefore is not subject to Section 18 liabilities.
Glucotrack (GCTK) filed its Q3 2025 10‑Q, reporting an operating loss of $4.3 million and a net loss of $4.2 million for the quarter. For the nine months ended September 30, 2025, net loss was $15.8 million.
Cash and cash equivalents were $7.9 million as of September 30, 2025, up from $5.6 million at year‑end, driven by financing inflows. During 2025, the company raised $10.7 million via equity sales (including ATM issuances) and received $3.0 million from a promissory note. Total assets were $8.3 million, liabilities $5.5 million, and stockholders’ equity $2.8 million. Shares outstanding were 910,688 as of November 13, 2025.
Management disclosed that conditions raise substantial doubt about the company’s ability to continue as a going concern. The company estimates it will require approximately $15.0 million to fund operations over the next twelve months and may seek additional equity or debt financing, including an equity line of up to $20.0 million. Product R&D advanced, with first‑in‑human study results presented and FDA pre‑IDE interactions underway, with an IDE submission expected in Spring 2026. The company also reported material weaknesses in internal control and ongoing remediation.
Glucotrack, Inc. permanently adjourned and cancelled its special stockholder meeting after failing to reach a quorum when it reconvened on November 7, 2025. The meeting was originally convened on October 31, 2025 and adjourned due to the absence of a quorum.
As of the September 23, 2025 record date, 158,370 shares of common stock were outstanding and entitled to vote, and 17.6% of those shares were represented in person or by proxy at the reconvened meeting, which did not constitute a quorum under the company’s bylaws. No business was conducted.
Glucotrack, Inc. (GCTK) adjourned its special stockholder meeting after failing to reach a quorum. As of the September 23, 2025 record date, 899,410 shares were outstanding and entitled to vote, and 16.4% were represented in person or by proxy.
Stockholders approved the Adjournment Proposal to solicit additional proxies, with 136,928 votes for, 8,655 against, and 1,923 abstentions. The meeting is adjourned to November 7, 2025 at 12:00 p.m. ET, accessible online at the provided meeting link. At the adjourned session, stockholders will be asked to vote on the Issuance Proposal as described in the company’s definitive proxy statement.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
